What is it about?
The aim of this study was to evaluate antiphosphatidylethanolamine antibody (aPE) investigation in patients SNAPS suspicion.
Featured Image
Why is it important?
Patients with clinical symptoms of APS but without aPL are defined as “seronegative APS” (SNAPS). Antiphosphatidylethanolamin have potentially a part in SNAPS and are underdiagnosis.
Perspectives
10% of patient with clinical criteria of APS and without conventional antiphospholipid antibodies have aPE. Results suggest the implication of aPE in SNAPS.
Paul Billoir
Rouen University Hospital Vascular Hemostasis Unit
Read the Original
This page is a summary of: Quelle place pour la recherche des anticorps antiphosphatidyléthanolamine dans la suspicion du syndrome des antiphospholipides séronégatif ?, La Revue de Médecine Interne, March 2019, Elsevier,
DOI: 10.1016/j.revmed.2018.11.013.
You can read the full text:
Contributors
The following have contributed to this page
